Long Shortz with Neurizon: FDA greenlight clears path for NUZ-001 to join landmark ALS trial

Stockhead’s Fraser Palamara chats with Neurizon Therapeutics (ASX: NUZ) managing director and CEO Dr Michael Thurn after the US FDA lifted the clinical hold on NUZ-001, clearing the way for its inclusion in the HEALEY ALS Platform Trial set to begin in Q4, 2025.

Dr Thurn says the FDA’s decision marks a major regulatory milestone that accelerates NUZ-001’s development and strengthens Neurizon’s position for future partnerships and platform expansion in neurodegenerative diseases.

Watch the latest to find out more.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.